Chemomab Therapeutics (CMMB) Interest Expenses (2017 - 2025)
Chemomab Therapeutics posted quarterly Interest Expenses of -$101000.0 for Q4 2025, up 59.6% year-on-year from -$63283.2 in Q4 2024, and down 199.02% on a QoQ basis from $102000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) has 7 years of Interest Expenses data on file, last reported at -$101000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 59.6% year-over-year to -$101000.0; the trailing twelve-month figure through Dec 2025 stood at $370000.0 (up 25.85% YoY), and the FY2025 full-year result was -$572000.0, up 27.96% from the prior year.
- Interest Expenses for Q4 2025 stood at -$101000.0, down from $102000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $480000.0 in Q2 2022 and bottomed at -$431000.0 in Q4 2023.
- The 4-year median for Interest Expenses is $137000.0 (2024), against an average of $29400.0.
- The widest annual swing landed in 2024, when Interest Expenses jumped 198.27%; it then tumbled 55.07% in 2025.
- A 4-year view of Interest Expenses shows it stood at -$380000.0 in 2022, then retreated by 13.42% to -$431000.0 in 2023, then jumped by 42.0% to -$250000.0 in 2024, then soared by 59.6% to -$101000.0 in 2025.
- The last three Interest Expenses figures came in at -$101000.0 (Q4 2025), $102000.0 (Q3 2025), and $205000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -101,000.00 |
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Dec 31, 2024 | -250,000.00 |
| Dec 31, 2024 | -250,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | -431,000.00 |
| Dec 31, 2023 | -431,000.00 |
| Sep 30, 2023 | -231,000.00 |
| Sep 30, 2023 | -231,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | 317,000.00 |
| Mar 31, 2023 | 317,000.00 |
| Dec 31, 2022 | -380,000.00 |
| Dec 31, 2022 | -380,000.00 |
| Sep 30, 2022 | -237,000.00 |
| Sep 30, 2022 | -237,000.00 |
| Jun 30, 2022 | 480,000.00 |
| Jun 30, 2022 | 480,000.00 |
| Jun 30, 2019 | -2.77 Mn |
| Jun 30, 2019 | -2.77 Mn |
| Dec 31, 2018 | -1.33 Mn |
| Dec 31, 2018 | -1.33 Mn |
| Jun 30, 2018 | 806,000.00 |
| Jun 30, 2018 | 806,000.00 |
| Dec 31, 2017 | -47,000.00 |
| Dec 31, 2017 | -47,000.00 |